



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Lazertinib

Item No. 29670

CAS Registry No.: 1903008-80-9
Formal Name: N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]-2-propenamide
Synonym: YH25448
MF: C₃₀H₃₄N₈O₃
FW: 554.6
Purity: ≥98%
UV/Vis.: λ_{max}: 296 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lazertinib is supplied as a solid. A stock solution may be made by dissolving the lazertinib in the solvent of choice, which should be purged with an inert gas. Lazertinib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of lazertinib in these solvents is approximately 0.2 and 3 mg/ml, respectively.

Lazertinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lazertinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Lazertinib has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lazertinib is an irreversible inhibitor of mutant EGFRs (IC₅₀s = 1.7, 2, and 3.3 nM for EGFR^{L858R/T790M}, EGFR^{Del19/T790M}, and EGFR^{Del19}, respectively).¹ It is selective for mutant EGFRs over wild-type EGFR, HER2, and HER4 (IC₅₀s = 76, 364, and 1,017 nM, respectively). Lazertinib reduces viability of Ba/F3 cells expressing mutant EGFRs (IC₅₀s = 3.3-5.7 nM). *In vivo*, lazertinib (1, 3, and 10 mg/kg) reduces tumor volume in an EGFR^{T790M} mutant H1975 non-small cell lung cancer (NSCLC) mouse xenograft model.

Reference

1. Yun, J., Hong, M.H., Kim, S.-Y., *et al.* YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. *Clin. Cancer Res.* **25**(8), 2575-2587 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/28/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM